Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...

In this cohort study, midlife hearing loss was linked with smaller brain volumes, faster decline in executive function, and a higher risk of developing dementia, particularly in those carrying the ...

Explore the alarming rise of early cardiac disease among corporate professionals in India, driven by long hours, stress, and ...

There are limits in applying AI to images of the heart, according to a new study from the Smidt Heart Institute at ...

According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...

Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of lifeTHE WOODLANDS, Texas, Nov. 08, 2025 ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

Julius Ryan D. Pronto, et al. Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation. Circulation Research (2025). DOI: https://doi.org/10.1161/CIRCRESAHA.124.325658 ...